why is there extramedullary hematopoiesis in myeloproliferative neoplasms?
Reading File
Finding Sources
Finding Sources
Searching PubMed
extramedullary hematopoiesis myeloproliferative neoplasms mechanism
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information to give a thorough answer. Let me compile it.
Extramedullary hematopoiesis (EMH) in myeloproliferative neoplasms (MPNs) is explained by two interrelated mechanisms: neoplastic stem cell homing and bone marrow failure from fibrosis. Here is a structured breakdown:
Why EMH Occurs in MPNs
1. Neoplastic Stem Cell Homing to Secondary Hematopoietic Organs
MPNs originate from a single mutant multipotent or pluripotent hematopoietic stem cell (HSC). A defining shared feature of all MPNs is the tendency of these neoplastic HSCs to home out of the bone marrow and take up residence in secondary hematopoietic organs - primarily the spleen, liver, and lymph nodes - where they resume proliferation.
This is not merely passive spillover; it represents an inherent property of the neoplastic clone. As Robbins puts it, this "variable homing of the neoplastic stem cells to secondary hematopoietic organs" is one of the four cardinal features shared across all MPNs, alongside increased proliferative drive, marrow fibrosis, and leukemic transformation risk.
The spleen and liver are the preferred sites because they retain the stromal microenvironmental niches that supported fetal hematopoiesis - meaning the circulating neoplastic HSCs can successfully engraft and produce blood cells there.
2. Bone Marrow Replacement by Fibrosis (the "Spent Phase")
This mechanism is most dramatic in primary myelofibrosis (PMF) but can occur as a late-stage "spent phase" in PV and ET as well.
The sequence is:
- Mutant megakaryocytes (driven by JAK2 V617F, CALR, or MPL mutations) inappropriately release platelet-derived growth factor (PDGF) and TGF-β into the marrow microenvironment.
- These factors are mitogens for non-neoplastic marrow fibroblasts. TGF-β also directly stimulates collagen deposition and angiogenesis.
- Progressive collagen fibrosis obliterates normal marrow hematopoietic niches, displacing HSCs out of the marrow and into the circulation.
- These circulating HSCs then seed the spleen, liver, and other sites, producing EMH.
As Robbins states directly: "As marrow fibrosis progresses, circulating neoplastic HSCs take up residence in niches in secondary hematopoietic organs, such as the spleen, the liver, and the lymph nodes, leading to the appearance of extramedullary hematopoiesis." - Robbins Pathologic Basis of Disease, p. 586
3. Why Red Cell Production at Extramedullary Sites is Ineffective
Even though HSCs successfully engraft outside the marrow, red cell production at these ectopic sites is disordered. The reasons are not fully elucidated, but the result is that despite massive splenomegaly (the spleen can reach several kg in myelofibrosis due to EMH), anemia still develops - a combination of suppressed marrow output and inefficient extramedullary erythropoiesis.
Key Molecular Drivers (Relevant to EMH)
| MPN | Primary Mutation | Mechanism |
|---|---|---|
| PV | JAK2 V617F (>95%) | Constitutive JAK2 kinase activation → erythropoietin-independent erythroid proliferation |
| PMF | JAK2 (~50-60%), CALR (~25-35%), MPL (~5-10%) | Megakaryocyte expansion → PDGF/TGF-β release → fibrosis → HSC displacement |
| ET | JAK2 (~50-60%), CALR, MPL | Similar to PMF, but fibrosis/EMH less prominent until late stages |
| CML | BCR-ABL fusion | Constitutive ABL kinase → massive myeloid expansion |
- Harrison's Principles of Internal Medicine 22E, p. 862
- Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 585-586
Sites of EMH in MPNs
- Spleen - most common; causes massive splenomegaly with portal hypertension
- Liver - infiltration of foci around portal venules, contributing to portal hypertension
- Lymph nodes
- Less common: paravertebral space (can cause cord compression), retroperitoneum, lungs/pleura, skin, bowel, genitourinary organs
Summary
EMH in MPNs is fundamentally due to the intrinsic migratory capacity of neoplastic HSCs, which home to fetal hematopoietic sites. In advanced disease (especially PMF and the spent phase of PV/ET), this is compounded by marrow fibrosis - driven by TGF-β and PDGF released from abnormal megakaryocytes - which physically evicts HSCs from the bone marrow, forcing them to establish hematopoiesis elsewhere. The result is characteristic massive splenomegaly, hepatomegaly, and cytopenias despite active blood cell production occurring throughout the body.
why is there increased risk of thrombosis in these neoplasms?
Finding Sources
Finding Sources
Reading File
Reading File
Searching PubMed
thrombosis myeloproliferative neoplasms JAK2 mechanism
I have enough to give a thorough, well-sourced answer now.
The increased thrombosis risk in MPNs is multifactorial, touching all three limbs of Virchow's triad. Here is a structured breakdown:
Mechanisms of Thrombosis in MPNs
1. Hyperviscosity from Erythrocytosis (most prominent in PV)
In polycythemia vera, the uncontrolled expansion of the red cell mass directly increases whole blood viscosity. This slows flow through vessels (stasis), causes engorgement, and promotes shear-stress-dependent platelet activation. As Harrison's puts it: "Uncontrolled erythrocytosis causes hyperviscosity, leading to neurologic symptoms such as vertigo, tinnitus, headache, visual disturbances, and transient ischemic attacks." Any vessel can be affected - cerebral, cardiac, and mesenteric vessels are most commonly involved. This is why phlebotomy to keep hematocrit below 45% is a cornerstone of PV management.
- Harrison's Principles of Internal Medicine 22E, p. 862
2. Quantitative Platelet Excess (ET and PV primarily)
A high platelet burden mechanically increases the probability of platelet-vessel wall contact and primary plug formation, especially in the microcirculation. Hepatic vein thrombosis (Budd-Chiari syndrome) and portal vein thrombosis are classic manifestations, and up to 50% of patients presenting with Budd-Chiari have an underlying MPN.
- Quick Compendium of Clinical Pathology, p. 743
- Yamada's Textbook of Gastroenterology, p. 1308
3. Qualitative Platelet Dysfunction - the Paradox
MPN platelets are not just increased in number - they are functionally abnormal. Two opposing defects can coexist:
- Pro-thrombotic: Increased platelet stickiness and activation, particularly relevant in erythromelalgia (burning pain in extremities from platelet-mediated microvascular occlusion). Erythromelalgia is a direct consequence of increased platelet reactivity in PV/ET.
- Pro-hemorrhagic: Paradoxically, in extreme thrombocytosis (platelet count >900,000/mL), the sheer mass of platelets absorbs and proteolytically cleaves high-molecular-weight von Willebrand multimers, causing acquired von Willebrand disease and a bleeding tendency.
Aggregometry in MPN platelets characteristically shows decreased aggregation and secretion in response to epinephrine, ADP, and collagen - reflecting receptor downregulation from chronic activation.
- Harrison's 22E, p. 862
- Quick Compendium of Clinical Pathology, p. 743
4. JAK2 V617F - a Direct Pro-thrombotic Effect on Blood Cells
The JAK2 V617F mutation (present in >95% of PV, ~50-60% of ET and PMF) does more than just drive proliferation. It confers pro-thrombotic properties directly onto the neoplastic cells:
- Granulocyte activation: JAK2 V617F granulocytes express increased tissue factor and form abnormal interactions with platelets and endothelium.
- Platelet hypersensitivity: JAK2-mutant platelets show increased surface P-selectin expression and hypersensitivity to thrombin and ADP.
- Endothelial activation: JAK2 V617F has been detected in endothelial cells in some patients, directly promoting a pro-thrombotic endothelial phenotype (increased VCAM-1, tissue factor expression).
- Neutrophil-platelet aggregates: Mutant neutrophils form more platelet-neutrophil aggregates, triggering platelet activation via cell-cell contact.
This explains why the thrombotic risk in PV/ET correlates not just with blood counts but with JAK2 mutant allele burden - patients with higher JAK2 V617F allele fractions have higher thrombotic risk.
A 2023 review by Barbui et al. specifically highlights that clonal hematopoiesis driven by JAK2 and other MPN driver mutations creates a systemic pro-thrombotic state beyond what blood counts alone would predict. [PMID: 37221411]
5. Unusual Thrombotic Sites
MPNs are notable for causing thrombosis at sites that are rare in the general population:
- Hepatic vein (Budd-Chiari syndrome) - particularly in young women with JAK2 V617F
- Portal and mesenteric veins - abdominal venous thrombosis
- Cerebral sinuses
- Splenic vein
Harrison's notes that PV should be suspected in any woman who develops hepatic vein thrombosis, since this is the only type of thrombosis strongly linked to JAK2 V617F expression. Clinically, an unexplained thrombosis in an unusual location should prompt JAK2 mutation testing.
Summary Table
| Mechanism | Primary MPN | Virchow's Limb |
|---|---|---|
| Hyperviscosity from erythrocytosis | PV | Stasis |
| Platelet mass (thrombocytosis) | ET, PV | Hypercoagulability |
| Platelet activation/stickiness (erythromelalgia) | PV, ET | Hypercoagulability |
| JAK2-driven neutrophil/platelet/endothelial activation | PV, ET, PMF | Hypercoagulability + endothelial injury |
| Acquired von Willebrand disease (extreme thrombocytosis) | ET | Paradoxical bleeding |
- Goldman-Cecil Medicine, p. 2197-2199
- Robbins Pathologic Basis of Disease, p. 585-586
- Harrison's Principles of Internal Medicine 22E, p. 862-863
This is a shared conversation. Sign in to Orris to start your own chat.